|
Milestones provides executive-level
market intelligence for the commercialization of new markets and
technologies for a broad range of purposes, including comprehensive
know-your-market needs assessment; "windows of opportunity" analysis;
non-dilutive investment strategies; reimbursement analysis and strategies; informal meetings with the US Food and
Drug Administration; and licensing and corporate partner negotiations.
_______
For Cognetix, a bioscience company
engaged in development of non-opiod pain analgesics for chronic back pain,
Milestones worked with executive and scientific staff to optimize
positioning against a major international pain management competitor with an
approved product, and introduced senior management to the US Army advanced
development program for possible collaborations.
_______
For Bayhill Therapeutics, Milestones
worked with executive, scientific and clinical development staff to envision
a patient recruitment and retention program for the company's multiple
sclerosis therapeutic. The program was constructed to assist Bayhill to
compete for principal investigators and to recruit patients for their
clinical trials in a market that had a number of competing clinical trials
for MS.
_______
For ProteoTech, a biotechnology company,
Milestones evaluated the over-the-counter and clinical use of a botanical
sourced from the Amazon rain forest for use in treatment of Alzheimer’s
disease and the prevention and dissolution of amyloid plaques in the brain.
The assessment was key in alliance discussions and negotiations for the
botanical, which were ultimately incorporated into two products sold through
two channels of distribution for the dietary field of use.
_______
For Paracel, an automated genomic
sequence and text analysis systems company, Milestones analyzed the genomics
markets for software and hardware products where speed, sensitivity and
selectivity are issues. The market research project was prologue to a
product launch at the Hilton Head, SC Human Genome Sequencing conference.
_______
For BioSpan, an image processing
software developer, Milestones performed an analysis of the commercial
opportunities and market
acceptance for the integration of image processing technology for desktop
publishing applications, resulting in the sale of the
desktop application to Aldus (Adobe), the leading graphics design software developer, and
2-1/2 years of funding for the client. In a second For a drug development tools
company, Milestones has performed a number of market research and
competitive comparative analyses to assist the company in its product
delivery strategies and services optimization.
_______
For Canyon Creek, an international
after-market parts and consumables company, Milestones collected data and
wrote the company’s business plan. Initially, the plan qualified the company for state economic development grant funding, and later for
negotiations among the company and a European water jet pump manufacturer, a
Canadian equipment manufacturer, and for negotiations with North American
distributors for the new systems.
_______
For BioSpace, an eCommerce company,
Milestones was retained to assist the product development team with a new
information channel that would be valued by core patrons of the site,
evolving the site from an information portal to an information hub.
_______
For LifeSpan, a bioscience services
firm ,
Milestones was retained to analyze market need, acceptance and timing for
the introduction of a technology driven-niche product. The analysis revealed
that a strategic alliance would be preferred and accepted vs.
traditional supplier relationships. Because market need was evolving,
the company learned that pre-alliance education was equally important and
that competition would come from where they least expected it.
_______
For Chiron, Milestones researched and
wrote a white paper positioning the company's various gene therapy programs
among sell-side analysts and other stakeholders.
_______
For LifeSpan, a bioscience services
firm, Milestones was retained to perform market analysis among existing
customers to advise the company on whether an outdated software program - a
front end to the company's service offerings - should be updated and for
insights into the product's deployment platform.
►
_______
For a specialty pharmaceutical company
[company requests anonymity], Milestones
was retained to analyze suspected fallout following a precipitous drop in
the company's market capitalization of $250 million, half the company’s value. Milestones
performed a perception analysis among pension fund managers and sell-side
analysts, 1k investors, trade reporters, and clinicians to ascertain the
company's communications effectiveness and credibility with important constituents. As a
result of its field work, Milestones was able to recommend corrective steps
to
the company’s executive management and board of directors, specifically
those policies relating to external communications. Within six months, the company’s market capitalization returned
to original levels. The analysis also
provided the founder and board of directors with insights for the transition
of the company's founder/CEO following the introduction of the company's
first product.
_______
For an eCommerce company [company requests anonymity], Milestones was retained to
assist the corporation through a founder transition, including a
comprehensive perception analysis among selected staff, board members and key
stakeholders outside the company, and to assist the organization to identify and
resolve issues relating to the successful transition of the company from an
emerging growth company to a publicly traded organization.
_______
For a biotechnology company [company requests anonymity], Milestones
negotiated a license agreement with a international dietary supplement
company for the dietary supplement field of use. Proceeds provided a revenue
stream for the biotechnology company's pharmaceutical drug research.
_______
For Canyon Creek, an industrial high
pressure water jet company, Milestones was retained to negotiate a
sublicense assignment for technology owned by a national laboratory.
Milestones assisted the company to develop a business plan, financial pro
forma and to identify investment capital to
commercialize the new technology following its integration as a new
division into the client company. ON TO PARTNER BIOS
►
For Government Practice Qualifications
►
|
